Mini-dose of thalidomide for treatment of primary myelofibrosis. Report of a case with complete reversal of bone marrow fibrosis and splenomegaly.

Abstract

We report a patient with very advanced myelofibrosis and huge splenomegaly who showed a complete hematological response to low dose thalidomide with reversal of splenomegaly and bone narrow fibrosis after 30 months of the treatment.

• Authors: Alain Berrebi, Edit Feldberg, Irena Spivak, Lev Shvidel
• Journal: Haematologica (Haematologica) Vol. 92 Issue 2 Pg. e15-6 (Feb 2007) ISSN: 1592-8721 [Electronic] Italy
• PMID: 17405746 (Publication Type: Case Reports, Journal Article)

Chemical References

• Angiogenesis Inhibitors
• Vitamin B Complex
• Thalidomide
• Folic Acid
• Fluoxymesterone
• Prednisone

Topics

• Aged, 80 and over
• Angiogenesis Inhibitors (administration & dosage, therapeutic use)
• Blood Transfusion
• Bone Marrow (pathology)
• Combined Modality Therapy
• Drug Therapy, Combination
• Fluoxymesterone (administration & dosage, therapeutic use)
• Folic Acid (administration & dosage, therapeutic use)
• Humans
• Male
• Prednisone (administration & dosage, therapeutic use)
• Primary Myelofibrosis (complications, drug therapy, pathology, therapy)
• Remission Induction
• Splenomegaly (etiology)
• Thalidomide (administration & dosage, therapeutic use)
• Vitamin B Complex (administration & dosage, therapeutic use)